Thursday, April 17th, 2025

DBS Group Shines in 2024: Record Profits, Rising Dividends & Bold Expansion Plans – Is This the Best Bank Stock to Own?

Is This the Best Bank Stock to Own?

DBS Group has delivered another record-breaking financial year in 2024, exceeding market expectations across key financial metrics such as net profit, return on equity (ROE), and net interest income (NII). The bank’s robust balance sheet, disciplined cost structure, and strategic growth plans continue to make it a compelling investment, despite varying analyst recommendations.

Other key financial institutions, including OCBC, UOB, and regional banks in Indonesia, Malaysia, and Thailand, are positioned for moderate to strong growth, each with distinct strategic priorities.


1. DBS Group: Financial and Strategic Highlights

2024 Performance Overview

  • Net Profit: Reached SGD 11.4 billion, up 10.9%-11% YoY across various reports.
  • Return on Equity (ROE): Strong at 18.0%, among the highest in developed market banks.
  • Total Income: Grew 10% YoY to SGD 22.3 billion.
  • Net Interest Margin (NIM): 2.15% in FY24, expected to decline slightly in 2025.
  • Dividend Yield: Estimated at 6.5%-6.8%, with a new capital return dividend of 15 cents per quarter.
  • Loan Growth: 3.5% YoY, with expected acceleration to 4.9%-5.4% in FY25.
  • Non-Interest Income: Grew 15% YoY, driven by 41% surge in wealth management fees.

Strategic Growth Priorities

  • Wealth Management (WM): Expanded 45% YoY, with 17% growth in AUM; remains a high ROE (~60%) segment.
  • Technology Investments: Generative AI (GenAI) is being integrated to enhance customer engagement and reduce costs.
  • Geographical Expansion: Looking into Malaysia’s Johor-Singapore Special Economic Zone (JS-SEZ) and possible MYR lending.
  • Capital Returns: SGD 3 billion share buyback program; possible EPS uplift of 2%.
  • Operational Efficiency: Cost-to-Income Ratio (CIR) at 39.9%-43.5%, benefiting from AI integration.

2. Market Sentiment & Broker Ratings for DBS

Broker Rating Target Price (SGD) Key Justifications
Maybank Research BUY 51.37 Strong ROE (15.8%), wealth management expansion, Malaysia growth
UOB Kay Hian HOLD 49.80 Dividend yield (6.6%-7.1%), Malaysia expansion, leadership transition
Lim & Tan Securities ACCUMULATE Not disclosed Capital return policy, high dividends, strong NIM
CGS International HOLD 43.00 Stable growth but concerns over digital disruptions and asset quality

Investor Implications

  • Positive Factors: High ROE, stable dividends, expansion in Malaysia, growth in wealth management, and capital returns.
  • Risks: Slight NIM decline expected (from 2.15% to 2.05% by 2025), higher provisions (specific allowances at 20bp), and uncertainty with the new CEO Tan Su Shan.

3. Peer Comparison: OCBC & UOB

OCBC Bank

  • Target Price: SGD 17.70 (5% upside)
  • ROE: 14.3% (CY24), declining to 12.8% (CY26)
  • Dividend Yield: 4.9% steady
  • Outlook: Moderate growth, strong cost efficiency, stable P/B ratio.

UOB

  • Target Price: SGD 39.50 (5.5% upside)
  • ROE: 13.4% (CY24), improving to 13.0%-12.8% (CY25-26)
  • Dividend Yield: 4.9%
  • Outlook: Steady regional expansion, digital transformation.

Comparison with DBS

Bank Target Price Upside ROE Dividend Yield
DBS Up to 17% (SGD 51.37) 18.0% (CY24), 15.8% (FY25-27E) 6.5%-6.8%
OCBC 5% (SGD 17.70) 14.3%-12.8% (CY24-26F) 4.9%
UOB 5.5% (SGD 39.50) 13.4%-12.8% (CY24-26F) 4.9%

4. Regional Bank Analysis

Indonesia

Bank Target Price Upside ROE Dividend Yield
Bank Mandiri (BMRI) 7.5% 20.7%-20.9% (CY24-26F) 7.1%-8.5%
Bank Rakyat Indonesia (BBRI) 1.3% 18.8%-19.4% (CY24-26F) 8.1%-9.3%

Malaysia

Bank Target Price Upside ROE Dividend Yield
Malayan Banking (MAY) 7.6% 10.5% 5.9%-6.4%
Public Bank (PBK) 6.1% 11.9% 4.5%

Thailand

Bank Target Price Upside ROE Dividend Yield
Bangkok Bank (BBL) 7.5% 8.1%-8.3% 4.9%
SCB X (SCB) 3.3% 8.8%-9.4% 8.9%

5. Market & Macroeconomic Trends

  • Singapore Market: FSSTI Index at 3,861.4, up 0.8% for the day.
  • Gold: USD 2,869.0, +9.3% YTD.
  • Oil: USD 71.0, up 0.6%.
  • Crude Palm Oil: USD 4,504.0, up 2.3%.
  • China PMI: Dropped to 50.1, indicating slow manufacturing recovery.
  • US Treasury Yields: 10-year forecast at 4.38%, Fed expected to cut rates twice in 2025.

6. Dividend Announcements

Company Dividend Announced
DBS Group 60 cents Q4 dividend (+15 cents capital return)
Nam Lee Pressed Metal 1.5 cents final, 0.5 cents special
Parkway Life REIT 2.38 cents final
CapitaLand Ascendas REIT 7.681 cents final
SGX 9 cents interim

7. Investment Outlook: DBS Remains a Strong Play

  • Bull Case: Target price of SGD 51.37 (Maybank) implies a 17% upside.
  • Bear Case: CGS International’s SGD 43.00 target reflects limited growth potential in the near term.
  • Dividend Yield (6.5%-7.1%) makes DBS an attractive income stock.
  • Malaysia expansion & AI-driven efficiencies could unlock further gains.

Final Investment Stance:

Strong long-term BUY for income-focused investors.
Short-term HOLD for cautious investors awaiting CEO transition clarity.
Slight NIM contraction (2.15% to 2.05%) not a major concern given strong capital returns.

Thank you

Value Partners Sees Hidden Gems in China A-Shares: Undervaluation and “Value-Up” Strategy Spark Recovery Hopes

Value Partners is making a compelling argument for why quality China A-shares may present significant upside potential, citing two major factors: deep undervaluation and Beijing’s push for a “value-up” strategy. The firm’s proprietary Free...

20x PE for Oriental Kopi IPO? Food Empire’s 8x Looks Like a Steal in Comparison

Johor’s Beloved Café Chain Goes Public, Shining a Spotlight on Singapore’s Hidden Gem Oriental Kopi, a beloved café chain in Malaysia known for its mouthwatering nasi lemak, creamy chendol, and delectable egg tarts, has...

Bumrungrad Hospital Stock: Attractive Valuation Despite Short-Term Challenges

Bumrungrad Hospital: An In-Depth Financial Analysis and Market Outlook Bumrungrad Hospital: An In-Depth Financial Analysis and Market Outlook Broker Name: Maybank Securities (Thailand) PCL Date of Report: November 19, 2024 Introduction Bumrungrad Hospital (BH)...